'Important milestone' for Mainstay as Dublin-based firm celebrates first sale of flagship back pain product
Dublin-based Mainstay Medical has succeeded in bringing its flagship back pain product to market for the first time.
ReActiv8 is an implantable neurostimulation system that is used to treat disabling chronic back pain.
The implant was performed by Dr Francis Kilian, Orthopedic and Neurosurgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz Germany.
"ReActiv8 represents a significant breakthrough for this large group of patients who are not candidates for spine surgery and fills an important void in our restorative treatment portfolio,” said Dr Kilian.
The Irish-listed company received the CE Mark approval for the implantable system last year, supported by positive clinical trials.
CEO Peter Crosby said that the first sale and implant of ReActiv8 is "an important milestone for Mainstay".
"We are fully committed to working with our customers to integrate ReActiv8 into their routine clinical practice and provide a new option for many people suffering from chronic low back pain,” he said.
ReActiv8 works by electrically stimulating the nerves responsible for contracting the key stabilising muscles of the lumbar spine.
Mainstay intends to focus on Germany for its commerical activities at present - but has ambitions to expand elsewhere "as the company gains experience and momentum".